NCT03093116 2026-05-27TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT04607421 2025-08-14A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPfizerPhase 3 Active not recruiting831 enrolled 2 FDA